Hepatitis B Vaccines - Pipeline Assessment and Market Forecasts to 2018







NEW YORK, Jan. 9, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Hepatitis B Vaccines - Pipeline Assessment and Market Forecasts to 2018
http://www.reportlinker.com/p0330264/Hepatitis-B-Vaccines---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Hepatitis B Vaccines - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Hepatitis B Vaccines - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global hepatitis b vaccines market. The report identifies the key trends shaping and driving the global hepatitis b vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hepatitis b vaccines sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimated the global hepatitis b vaccines market at $997.0m in 2010, and forecast it to grow at a compound annual growth rate (CAGR) of 4.1% for the next eight years, to reach $1,376.1m by 2018. During the period 2005–2010, the market grew at a CAGR of 6.7%, from $720.5m to $997.0. The growth is primarily attributed to the increase in the vaccination rate and coverage among different age groups, as a result of government programs and increased public awareness. The market would also be driven by birth population growth and the need for therapeutic vaccines in cases of cirrhosis, liver disease, and primary liver cancer (hepatocellular carcinoma or HCC).

Scope

The report provides information on the key drivers and challenges of the hepatitis b vaccines market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) hepatitis b vaccines market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, type of vaccines being developed and emerging trends by seven key markets. Pipeline candidates fall under major classes such as single antigen vaccine, combinational vaccine and others.
- Analysis of the current and future competition in the seven key countries hepatitis b vaccines market. Key market players covered are Dynavax Technologies Ltd., Merck, GlaxoSmithKline, Sanofi, GenPhar, LG Life Sciences, Genexine and NanoBio Corp.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the hepatitis b vaccines therapeutics market.
- Analysis of key recent licensing and partnership agreements in hepatitis b vaccines market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global hepatitis b vaccines market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global hepatitis b vaccines market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global hepatitis b vaccines market landscape? – Identify, understand and capitalize.



1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Hepatitis B - Introduction 7
2.1 Overview 7
2.2 Epidemiology 9
2.3 Etiology 11
2.4 Symptoms 12
2.5 Diagnosis 12
2.6 Pathophysiology 15
2.7 Treatment and Management Pattern 17
2.8 GlobalData Pipeline Report Guidance 21
3 Hepatitis B Vaccines Therapeutics - Market Characterization 22
3.1 Hepatitis B Vaccines Market Size (2005-2010) – Global 22
3.2 Hepatitis B Vaccines Market Forecast (2010-2018) – Global 23
3.3 Hepatitis B Vaccines Market Size (2005-2010) – The US 24
3.4 Hepatitis B Vaccines Market Forecast (2010-2018) – The US 25
3.5 Hepatitis B Vaccines Market Size (2005-2010) – France 26
3.6 Hepatitis B Vaccines Market Forecast (2010-2018) – France 27
3.7 Hepatitis B Vaccines Market Size (2005-2010) – Germany 28
3.8 Hepatitis B Vaccines Market Forecast (2010-2018) – Germany 29
3.9 Hepatitis B Vaccines Market Size (2005-2010) – Italy 30
3.10 Hepatitis B Vaccines Market Forecast (2010-2018) – Italy 31
3.11 Hepatitis B Vaccines Market Size (2005-2010) – Spain 32
3.12 Hepatitis B Vaccines Market Forecast (2010-2018) – Spain 33
3.13 Hepatitis B Vaccines Market Size (2005-2010) – The UK 34
3.14 Hepatitis B Vaccines Market Forecast (2010-2018) – The UK 35
3.15 Hepatitis B Vaccines Market Size (2005-2010) – Japan 36
3.16 Hepatitis B Vaccines Market Forecast (2010-2018) – Japan 37
3.17 Drivers and Barriers for the Hepatitis B Vaccines Market 38
3.17.1 Drivers for the Hepatitis B Vaccines Market 38
3.17.2 Barriers for the Hepatitis B Vaccines Market 38
3.18 Opportunity and Unmet Need 39
3.19 Key Takeaway 40
4 Hepatitis B Vaccines Market - Competitive Assessment 41
4.1 Overview 41
4.2 Strategic Competitor Assessment 41
4.3 Product Profile for the Major Marketed Products in the Hepatitis B Vaccines Market 42
4.3.1 Recombivax HB 42
4.3.2 Engerix-B 43
4.3.3 Twinrix 44
4.3.4 Comvax 45
4.3.5 Pediarix 45
4.4 Major Marketed Products Comparison in the Hepatitis B Vaccines Market 47
4.5 Key Takeaway 48
5 Hepatitis B Vaccines - Pipeline Assessment 49
5.1 Overview 49
5.2 Strategic Pipeline Assessment 49
5.3 Hepatitis B Vaccines – Pipeline Analysis by Phase of Development 49
5.3.1 Hepatitis B Vaccines – Filed and Phase III Pipeline 49
5.3.2 Hepatitis B Vaccines – Phase II Pipeline 49
5.3.3 Hepatitis B Vaccines – Phase I Pipeline 50
5.3.4 Hepatitis B Vaccines – Pre-clinical and Discovery Pipeline 50
5.4 Hepatitis B Vaccines – Pipeline by Type of Vaccines 51
5.5 Technology Trends Analytical Framework 52
5.6 Most Promising Drug Profiles 53
5.6.1 Heplisav 53
5.6.2 Hexaxim 54
5.6.3 Pediatric Hexavalent Vaccine (V419) 54
5.6.4 DTwP-HB-Hib (Recon) Vaccine 55
5.7 Key Takeaway 55
6 Hepatitis B Vaccines - Clinical Trials Mapping 56
6.1 Clinical Trials by Region/Country (the US, EU5, and Japan) 56
6.2 Clinical Trials by Phase of Clinical Development 57
6.3 Clinical Trials by Trial Status 58
6.4 Clinical Trials by Sponsors 59
6.5 Top Companies Participating in Hepatitis B Vaccines Clinical Trials 61
7 Hepatitis B Vaccines Market - Strategic Assessment 62
7.1 Key Events Impacting the Future Market 62
7.2 Future Market Competition Scenario 63
8 Hepatitis B Vaccines Market - Future Players 64
8.1 Introduction 64
8.2 Company Profiles 65
8.2.1 Sanofi 65
8.2.2 GlaxoSmithKline 67
8.2.3 Dynavax Technologies Corporation 69
8.2.4 LG Life Sciences Ltd 70
8.2.5 Merck & Co., Inc. 71
8.3 Details of Other Companies in the Pipeline 73
8.4 Key Takeaway 75
9 Hepatitis B Vaccines - Licensing and Partnership Deals 76
10 Hepatitis B Vaccines - Appendix 77
10.1 Definitions 77
10.2 Acronyms 77
10.3 Research Methodology 78
10.3.1 Coverage 79
10.3.2 Secondary Research 79
10.3.3 Forecasting 79
10.3.4 Primary Research 81
10.3.5 Expert Panel Validation 82
10.4 Contact Us 82
10.5 Disclaimer 82
10.6 Bibliography 82

List of Tables

Table 1: Hepatitis B – Nomenclature of Hepatitis B 8
Table 2: Hepatitis B – Laboratory Nomenclature 14
Table 3: Hepatitis B – Approved Vaccines for Hepatitis B 18
Table 4: Hepatitis B – Approved Drugs for Hepatitis B 18
Table 5: Hepatitis B Vaccines Market, Global, Revenue ($m), 2005–2010 22
Table 6: Hepatitis B Vaccines Market, Global, Forecast ($m), 2010–2018 23
Table 7: Hepatitis B Vaccines Market, The US, Revenue ($m), 2005–2010 24
Table 8: Hepatitis B Vaccines Market, The US, Forecast ($m), 2010–2018 25
Table 9: Hepatitis B Vaccines Market, France, Revenue ($m), 2005–2010 26
Table 10: Hepatitis B Vaccines Market, France, Forecast ($m), 2010–2018 27
Table 11: Hepatitis B Vaccines Market, Germany, Revenue ($m), 2005–2010 28
Table 12: Hepatitis B Vaccines Market, Germany, Forecast ($m), 2010–2018 29
Table 13: Hepatitis B Vaccines Market, Italy, Revenue ($m), 2005–2010 30
Table 14: Hepatitis B Vaccines Market, Italy, Forecast ($m), 2010–2018 31
Table 15: Hepatitis B Vaccines Market, Spain, Revenue ($m), 2005–2010 32
Table 16: Hepatitis B Vaccines Market, Spain, Forecast ($m), 2010–2018 33
Table 17: Hepatitis B Vaccines Market, The UK, Revenue ($m), 2005–2010 34
Table 18: Hepatitis B Vaccines Market, The UK, Forecast ($m), 2010–2018 35
Table 19: Hepatitis B Vaccines Market, Japan, Revenue ($m), 2005–2010 36
Table 20: Hepatitis B Vaccines Market, Japan, Forecast ($m), 2010–2018 37
Table 21: Antibody Responses Following PEDIARIX as Compared to Separate Concomitant Administration of INFANRIX, ENGERIX-B, and IPV (One Month After Administration of Dose 3) 46
Table 22: Hepatitis B Vaccines Market, Global, Major Marketed Products Comparison, 2011 47
Table 23: Hepatitis B Vaccines – Filed and Phase III Clinical Pipeline, 2011 49
Table 24: Hepatitis B Vaccines – Phase II Clinical Pipeline, 2011 49
Table 25: Hepatitis B Vaccines – Phase I Clinical Pipeline, 2011 50
Table 26: Hepatitis B Vaccines – Pre-Clinical and Discovery Pipeline, 2011 50
Table 27: Hepatitis B Vaccines, Global, Clinical Trials, 2011 56
Table 28: Hepatitis B Vaccines, Global, Clinical Trials by Phase, 2011 57
Table 29: Hepatitis B Vaccines, Global, Clinical Trials by Status of Development, 2011 58
Table 30: Hepatitis B Vaccines, Global, Overall Sponsors, 2011 59
Table 31: Hepatitis B Vaccines, Global, Prominent Sponsors, 2011 60
Table 32: Hepatitis B Vaccines, Global, Top Ten Companies by Phase, 2011 61
Table 33: Sanofi - Vaccines Pipeline Portfolio, 2011 67
Table 34: GlaxoSmithKline - Vaccines Pipeline Portfolio, 2011 69
Table 35: Dynavax Technologies Corporation – Vaccine Pipeline Products, 2011 70
Table 36: LG Life Sciences – Vaccines Pipeline Portfolio, 2011 71
Table 37: Merck & Co., Inc. – Vaccine Pipeline Portfolio, 2011 72
Table 38: Description of Other Companies in the Pipeline, 2011 73
Table 39: Hepatitis B Vaccines, Global, Deals, 2011 76

List of Figures

Figure 1: Structure of Hepatitis B Virus 7
Figure 2: Genotype of Hepatitis B Virus and its Geographical Distribution 8
Figure 3: Summary of Hepatitis B Virus Characteristics 9
Figure 4: Hepatitis B – Prevalence of HBV Infection in the World by Country 10
Figure 5: Hepatitis B – Areas and Features of Hepatitis B Prevalence 10
Figure 6: Geographic Patterns of Hepatitis B Disease Burden 11
Figure 7: Hepatitis B – Interpretation of Hepatitis B Virus Serology 15
Figure 8: Hepatitis B – Life Cycle of HBV 16
Figure 9: Hepatitis B – Spectrum of Liver Disease After HBV Infection 17
Figure 10: Hepatitis B – Childhood Vaccination Schedule 20
Figure 11: Hepatitis B Vaccines Market, Global, Revenue ($m), 2005–2010 22
Figure 12: Hepatitis B Vaccines Market, Global, Forecast ($m), 2010–2018 23
Figure 13: Hepatitis B Vaccines Market, The US, Revenue ($m), 2005–2010 24
Figure 14: Hepatitis B Vaccines Market, The US, Forecast ($m), 2010–2018 25
Figure 15: Hepatitis B Vaccines Market, France, Revenue ($m), 2005–2010 26
Figure 16: Hepatitis B Vaccines Market, France, Forecast ($m), 2010–2018 27
Figure 17: Hepatitis B Vaccines Market, Germany, Revenue ($m), 2005–2010 28
Figure 18: Hepatitis B Vaccines Market, Germany, Forecast ($m), 2010–2018 29
Figure 19: Hepatitis B Vaccines Market, Italy, Revenue ($m), 2005–2010 30
Figure 20: Hepatitis B Vaccines Market, Italy, Forecast ($m), 2010–2018 31
Figure 21: Hepatitis B Vaccines Market, Spain, Revenue ($m), 2005–2010 32
Figure 22: Hepatitis B Vaccines Market, Spain, Forecast ($m), 2010–2018 33
Figure 23: Hepatitis B Vaccines Market, The UK, Revenue ($m), 2005–2010 34
Figure 24: Hepatitis B Vaccines Market, The UK, Forecast ($m), 2010–2018 35
Figure 25: Hepatitis B Vaccines Market, Japan, Revenue ($m), 2005–2010 36
Figure 26: Hepatitis B Vaccines Market, Japan, Forecast ($m), 2010–2018 37
Figure 27: Opportunity and Unmet Need in the Hepatitis B Vaccines Market, 2011 39
Figure 28: Strategic Competitor Assessment of the Marketed Products in Hepatitis B Vaccines, 2011 41
Figure 29: Hepatitis B Vaccines, Clinical Pipeline by Mechanism of Action (%), 2011 51
Figure 30: Hepatitis B Vaccines – Clinical Pipeline by Phase of Development (%), 2011 51
Figure 31: Technology Trends Analytics Framework, 2011 52
Figure 32: Technology Trends Analytical Framework – Description, 2011 52
Figure 33: Hepatitis B Vaccines, Global, Clinical Trials by Country, 2011 56
Figure 34: Hepatitis B Vaccines, Global, Clinical Trials by Phase (%), 2011 57
Figure 35: Hepatitis B Vaccines, Global, Clinical Trials by Status of Development (%), 2011 58
Figure 36: Hepatitis B Vaccines, Global, Overall Sponsors (%), 2011 59
Figure 37: Hepatitis B Vaccines, Global, Prominent Sponsors (%), 2011 60
Figure 38: Hepatitis B Vaccines, Global, Top Companies by Phase, 2011 61
Figure 39: Hepatitis B Vaccines Market, Drivers and Barriers, 2011 62
Figure 40: Implications for Future Market Competition in the Hepatitis B Vaccines Market, 2011 63
Figure 41: Hepatitis B Vaccines Market, Clinical Pipeline by Company, 2011 64
Figure 42: GlobalData Market Forecasting Model 81

Companies mentioned
Sanofi
GlaxoSmithKline
Dynavax Technologies Corporation
LG Life Sciences Ltd
Merck & Co., Inc.





To order this report:
Drug and Medication Industry: Hepatitis B Vaccines - Pipeline Assessment and Market Forecasts to 2018


More  Market Research Report



Check our  Industry Analysis and Insights


CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.